PRECIGEN, INC. (PGEN) research
PRECIGEN, INC.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $8.54
- As of
PRECIGEN, INC. (PGEN): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-04.
As of . Source: SEC EDGAR filings for PGEN. Method and limitations.
Share the PGEN intelligence card
See the full PGEN dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for PGEN on one page. Preview it with sample data, then open it live with a free account.
Preview the PGEN dossierActive signals for PGEN
- highCONSENSUS_BUY
3 tracked funds increased PGEN this 2026Q2, institutional consensus
- highCONSENSUS_BUY
4 tracked funds increased PGEN this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +1199% to PGEN (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +69% to PGEN (2026Q2)
- mediumNEW_POSITION
RENAISSANCE TECHNOLOGIES LLC new position in PGEN
FREE, NO ACCOUNT
Every signal on PGEN, as it fires
You are seeing 5 of 17 signals recorded on PGEN since 2026-05-30.
The five above landed across 2 days. The other 12 were recorded on 4 other days. 9 of the 17 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in PGEN (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| Point72 Asset Management, L.P.CUSIP 74017N105 · 2026Q2 | $7.2M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 74017N105 · 2026Q2 | $4.7M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 74017N105 · 2026Q2 | $3.5M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 74017N105 · 2026Q2 | $781K | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 74017N105 · 2026Q2 | $575K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, PGEN
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
PGEN against its peers
PGEN's operating margin of -1141.1% ranks in the 39th percentile of 13 Biotechnology sub-industry peers, fiscal periods ending between 2025-11-30 and 2025-12-31.
| Metric | PGEN | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 9.7M USD | 51.9M USD | 30 | 14 |
| Operating margin | -1141.1% | -512.9% | 39 | 13 |
| Net margin | -2588.2% | -483.6% | 25 | 13 |
| Return on equity | -1198.6% | -33.5% | 2 | 23 |
Peers (23): MBX, ATAI, NAMS, QURE, ZLAB, DYN, CLDX, BEAM, IRON, IMNM, NRIX, SLS, RCUS, VERA, DNLI, VRDN, ELVN, GRTX, ARQT, ADMA, MLYS, ACAD, PHVS. Left out: ZLDPF (no annual filing), ADRX (no annual filing). Fiscal periods ending between 2025-11-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (PGEN: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more PGEN signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to PGENand get the insider, 13F, options, and confluence read in one view.